Robert Pitts is an Infectious Disease physician affiliated with NYU Langone Health. OpenAlex indexes 31 publications with 238 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
550 1st Ave
New York, NY 100166402
Telephone
301-318-4376Provider last certified this registry record 8 Sept 2022.
Clinical trials
- Expanding PrEP By Embedding Unannounced SNAPS Navigators in High STI Testing Clinical Sites
Sponsor: NYU Langone Health
Overall officialCompletedNCT04207151
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202515 payments
- ViiV Healthcare CompanyProgram year20251 payment
- ViiV Healthcare CompanyProgram year202412 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
31.3%Statin11.6%Atorvastatin Calcium100%Part D≥12 patientsCalcium channel blocker8.1%Amlodipine Besylate100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
21.3%GLP-1 receptor agonist9.7%Ozempic60%Trulicity40%Part D<11 patientsBiguanide (metformin)6.1%Metformin Hcl100%Part D<11 patients+ 1 more class in this area
Anti-infectives
13.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor7.4%Juluca52%Cabenuva48%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor6.1%Emtricitabine-Tenofovir Disop100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gareth Morgan, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
Ira Jacobson, MD
NYU Langone Health
Michael Zelefsky, MD
NYU Langone Health
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”